Arcus Biosciences, Inc. (RCUS)
NYSE: RCUS · IEX Real-Time Price · USD
14.28
-0.45 (-3.05%)
Jul 19, 2024, 4:00 PM EDT - Market closed
Arcus Biosciences Stock Forecast
Stock Price Forecast
The 10 analysts with 12-month price forecasts for Arcus Biosciences stock have an average target of 39.3, with a low estimate of 23 and a high estimate of 70. The average target predicts an increase of 175.21% from the current stock price of 14.28.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for RCUS stock from 11 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 5 | 5 |
| Buy | 4 | 4 | 4 | 4 | 4 | 5 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 9 | 9 | 10 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Buy Maintains $35 → $25 | Buy | Maintains | $35 → $25 | +75.07% | Jul 8, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Jul 5, 2024 |
| Truist Securities | Truist Securities | Strong Buy Maintains $50 → $44 | Strong Buy | Maintains | $50 → $44 | +208.12% | Jun 24, 2024 |
| Citigroup | Citigroup | Strong Buy Maintains $36 → $38 | Strong Buy | Maintains | $36 → $38 | +166.11% | Jun 3, 2024 |
| Wedbush | Wedbush | Buy Reiterates $30 | Buy | Reiterates | $30 | +110.08% | May 9, 2024 |
Financial Forecast
Revenue This Year
214.35M
from 117.00M
Increased by 83.21%
Revenue Next Year
184.85M
from 214.35M
Decreased by -13.76%
EPS This Year
-3.61
from -4.15
EPS Next Year
-4.35
from -3.61
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 278.3M | 551.1M | 600.0M | 416.0M | 871.8M |
| Avg | 214.4M | 184.9M | 237.2M | 257.1M | 508.7M |
| Low | 98.0M | 88.2M | 88.2M | 84.4M | 286.9M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 137.8% | 157.1% | 224.6% | 75.4% | 239.1% |
| Avg | 83.2% | -13.8% | 28.3% | 8.4% | 97.8% |
| Low | -16.2% | -58.9% | -52.3% | -64.4% | 11.6% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -2.46 | -2.54 | -1.65 | -5.24 | -2.98 |
| Avg | -3.61 | -4.35 | -3.86 | -5.09 | -2.90 |
| Low | -4.82 | -5.38 | -6.22 | -4.89 | -2.78 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.